Fuso Pharmaceutical Industries,Ltd. Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Non-consolidated)

Business Performance Overview

Fuso Pharmaceutical Industries,Ltd. reported in its interim financial summary for the fiscal year ending March 2027 that net sales were 32,395 million yen (Year-over-Year +3.7%), operating income was 1,743 million yen (Year-over-Year +39.7%), ordinary income was 1,434 million yen (Year-over-Year +26.8%), and interim net income was 1,041 million yen (Year-over-Year +25.2%). The increase in sales was attributed to deeper market penetration of core products and promotional efforts for generics; milestone revenue related to the domestic clinical trial of DMX-200 was not recognized in this period. Financially, total assets were 91,284 million yen, net assets were 36,639 million yen, and the equity ratio improved to 40.1% compared with the end of the previous fiscal year.

Outlook and Dividends

The company revised its full-year earnings forecast from the previously announced projection and also disclosed an increase in the year-end dividend forecast on the same date. Revisions to the full-year outlook and dividend policy based on interim results may affect the company's capital policy and financial stability; investors should monitor the latest full-year guidance disclosures closely.